mTORC1-selective therapeutics for rare and age-related diseases
Very little changed from August 15, 2020 to January 25, 2021 to January 24, 2022. The core claim stayed fixed: Aeovian thinks aberrant mTORC1 activation is part of the problem in rare and age-related disease, and that you should inhibit mTORC1 while leaving mTORC2 alone. Same thesis, same villain, same promised payoff: better safety, tolerability, compliance, and efficacy than blunt non-selective mTOR inhibitors. What did change was mostly framing. In 2020 the pitch is broad and mechanistic: stress-related disease mechanisms plus mTORC1 dysregulation. By 2021 the language gets tidier and more assertive, with extra emphasis on selective pathway modulation, aging and genetic mutations as causes of abnormal mTORC1 activation, and explicit contrast with metabolic and immune toxicities from non-selective inhibitors. In 2022 they widen the list of upstream drivers to include oxidative, cellular, and environmental stress. That is a refinement, not a pivot. So the belief evolution here is shallow. The company did not reverse itself, narrow the indication logic, or introduce a new therapeutic doctrine. It polished the same story and added a bit more biological texture. Fair enough, but let's not pretend three versions of the same homepage thesis amount to a scientific turn. Evidence is thin because these entries are all company statements, not clinical readouts or external validation. They show message stability, not whether the idea works. Those are different things, and companies are famously capable of confusing them when nobody makes them stop.